BridgeBio Pharma, Inc.
BBIO· Nasdaq
BBIOBridgeBio Pharma, Inc.
Filed Nov 5, 2020 · 10-Q · 36 days after period end · 0001564590-20-051460
| Metric | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|
| Revenue | $8.13M | $26.74M | — |
| Net Income | -$130.17M | -$60.66M | -$42.08M |
| EPS Diluted | -$0.98 | -$0.51 | -$0.52 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BridgeBio Pharma, Inc. · CIK 1743881 · Engraved from SEC EDGAR
ended Sep 30, 2020 · filed Nov 5, 2020 · 36 d after period end
